Astellas and FibroGen's Evrenzo (roxadustat) Receive EC's Approval for Symptomatic Anemia Associated with Chronic Kidney Disease
Shots:
- The approval is based on the P-III program including 8 studies evaluating Evrenzo in 9600 patients with symptomatic anemia associated with CKD- regardless of dialysis status & prior ESA treatment. Following the EC's approval- FibroGen to receive $120M milestones along with royalties based upon EU sales
- The results demonstrated that the therapy was effective in maintaining target Hb levels & safety profile is reflective for CKD populations compared to ESAs
- Roxadustat is a HIF-PH inhibitor & is approved in EU member states- including the EEA countries- Japan- China- Chile & South Korea for the same indication in adult patients on DD & NDD
| Ref: Astellas | Image:Astellas
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com